EGFR and melanoma: Here, we demonstrate for the first time that, in a syngeneic B16 melanoma model engineered to express a human/murine hybrid epidermal growth factor receptor (EGFR), a fractional-dose regimen of DTIC effectively complements the subsequent adoptive transfer of murine CAR T cells specific to the hybrid EGFR.